Back

Artivion Inc

Ticker: AORT ISIN: US2289031005
Add to portfolio Portfolio analysis in 2min
Stock Small-cap High beta
Market cap
$1.83B
P/E
179.81
Forward P/E
61.35
Profit margin
2.21%
Revenue growth QoQ
19.20%
Beta
1.62
$27.20 3.11%
Price as of 2026-08-26 · NYSE

Performance by timeframe

Rolling returns
1 Month +4.21%
6 Months -23.98%
1 Year -38.22%
5 Years +0.95% p.a.+4.82%
10 Years +5.20% p.a.+65.95%
Since inception -0.77% p.a.-17.56%
Calendar year returns
YTD -40.36%
2025 +59.53%
2024 +59.90%
2023 +47.52%
2022 -40.44%
2021 -13.81%

Key stats

Market cap
1.83B
P/E
179.81
Beta
1.62
52-week range
23.04 - 48.25
50-day MA
36.84
200-day MA
40.53
Section 1

Business overview

Company profile data from fundamentals.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Sector Healthcare
Industry Medical Devices
Country United States
Exchange NYSE
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 2.70%
ROA 2.34%
Profit margin 2.21%
Operating margin 8.09%
PEG ratio 181.50
Revenue/share TTM 9.73
Revenue TTM 441.33M
EBITDA 53.80M
Gross profit TTM 284.23M
Beta 1.62

Valuation

Trailing P/E 179.81
Forward P/E 61.35
P/B 4.09
P/S 4.15
EV/EBITDA 31.71
EV/Revenue 4.59
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 0.81
Quarterly earnings growth 0.00%
Revenue TTM 441.33M
Reported quarters 114
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Ex-dividend date 2015-12-09
Split factor 3:2
Last split date 2000-12-28
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $33.17
Analyst rating 4.6667

Ownership & short interest

Shares outstanding 41.92M
Shares float 34.53M
Institutional ownership 87.72%
Insider ownership 5.48%
Short ratio 4.32
Short % of float 4.82%

Details

Instrument metadata and source update timestamps.

Symbol AORT
Name Artivion Inc
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US2289031005
Country USA
Code + exchange AORT.NYSE
Fundamentals updated 2026-04-28

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.